Monday, July 24, 2023 6:17:53 PM
At close: 4:00 PM EDT (Eastern Daylight Time)
$3.17 + $0.22 (+7.46%)
After hours: 4:44 PM EDT
$3.25 + $0.08
Then, 16 minutes later
After hours: 5:00 PM EDT
$3.30 + $0.13
After hours: 5:15 PM EDT
$3.3900 + $0.22 (which is how much it climbed in the entire day's trading = + 6.94% from the close
Previously
For the first fiscal quarter that ended June 30, 2023, the Company reported an increase in revenue which represents growth of over 40% Year Over Year from the corresponding prior-year quarter.
Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, commented, "Based on robust first-quarter revenue growth and our early read on the quarter's sales and operating metric trends - including customer retention -- I am fully confident our business will continue to scale as planned and show strong growth throughout the fiscal year 2024.
"Our products and biosphere platform model, and vertical sales strategy of complementary products, continues to strengthen," Dr. Waqaas added. "Since launching our Biocare app in January of this year, we have had over 10,000 downloads. Our second product -- BiotresTM- is rapidly gaining traction industrywide with new and existing customer purchases exceeding our internal forecast. It will set a company record for its $2 million run rate."
Bitricity will continue accelerating its growth in the coming years as it expands its presence in the U.S. market and additionally, expands globally.
Recent BTCY News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 10:02:19 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 10:18:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 10:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:55:34 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 10/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 12:15:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/19/2023 08:57:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 12:38:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:26:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:14:24 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 07/17/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 08:05:35 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 09:29:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM